Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million
AUSTIN, Texas, May 03, 2024 (GLOBE NEWSWIRE) — Aileron Therapeutics, Inc. (“Aileron”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel […]